Journal
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Volume 91, Issue 2, Pages 199-204Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2018.01.029
Keywords
Oritavancin; Lipoglycopeptide; Gram-positive cocci
Categories
Funding
- Medicines Company (Parsippany, NJ) via the SENTRY Antimicrobial Surveillance Program platform
- Medicines Company
Ask authors/readers for more resources
The in vitro activity of oritavancin was assessed against 44,715 gram-positive pathogens causing infections in European and United States (US) hospitals (2010-2014). There were no substantive differences (>+/- 2-fold dilution) in oritavancin MIC50 or MIC90 values for different species/organism groups over time or by region. Oritavancin (99.9% susceptible) showed modal MIC, MIC50, and MIC90 results of 0.03, 0.03, and 0.06-0.12 mg/L when tested against Staphylococcus aureus, regardless of methicillin susceptibility, year, or region. Coagulase-negative staphylococci from the US and Europe demonstrated equal MIC50 values for oritavancin (MIC50), 0.03 mg/L). Oritavancin inhibited 99.9% of Enterococcus faecalis and all E. faecium at <= 0.15 mg/L, including vancomycin-resistant isolates. Oritavancin exhibited MIC50 results of 0.03 and <= 0.008 mg/L when tested against beta-hemolytic and viridans group streptococci isolates, respectively, regardless of geographical region. Oritavancin maintained potent activity in vitro against this contemporary collection of European and US gram-positive isolates over 5 years (2010-2014). (C) 2018 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available